Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Cellectar Biosciences, Inc. (CLRB)
Last cellectar biosciences, inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cellectar.com
Company Research
Source: GlobeNewswire
INDIANAPOLIS and FLORHAM PARK, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpectronRx, a leading radiopharmaceutical contract developer and manufacturer, and Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, have signed a commercial supply agreement for the manufacture of Cellectar’s first-in-class cancer therapy, iopofosine I 131. "We continue strengthening our supply network, ensuring patients with advanced cancers in need of novel therapeutic options gain access to what we believe is a best-in-class treatment for Waldenstrom's macroglobulinemia (WM). This partnership is part of our multi-sourced global supply strategy, which is key for Cellectar’s commercialization plans for iopofosine I 131," said James Caruso, president and CEO of Cellectar. "SpectronRx's expertise and strategically located facilities offer significant logistical benefits for
Show less
Read more
Impact Snapshot
Event Time:
CLRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLRB alerts
High impacting Cellectar Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CLRB
News
- NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]Yahoo! Finance
- NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire
- Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.MarketBeat
- Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate UpdateGlobeNewswire
CLRB
Earnings
- 11/18/24 - Miss
CLRB
Sec Filings
- 11/18/24 - Form 8-K
- 11/18/24 - Form 10-Q
- 11/15/24 - Form 8-K
- CLRB's page on the SEC website